Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting System
This study indicates that the types of adverse events may vary by PARP inhibitor and by country. These results will be beneficial in clinical practice.
Authors
- Chihiro Shiraishi (ORCID: https://orcid.org/0000-0002-1190-6540)
- Toru Ogura (ORCID: https://orcid.org/0000-0002-6343-5349)
Institutions
- Mie University Hospital (JP)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1080/14740338.2024.2418333
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00